Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominantly inherited predisposition to neoplastic lesions of the parathyroids, pancreas, and the pituitary. We have previously located the predisposing genetic defect to the long arm of chromosome 11 by genetic linkage. In this study, 124 members of six MENi families, including 59 affected individuals, were genotyped for restriction fragment length polymorphisms with different DNA probes, and the genetic linkage between these marker systems and MENi was determined. 13 marker systems (17 DNA probes) were found to be linked to MEN1. These markers are located within a region on chromosome 11 spanning 14% meiotic recombinations, with the MENi locus in the middle. Four of the marker systems are on the centromeric side of MEN1, and four on the telomeric side, based on meiotic crossovers. The remaining five DNA probes are closely linked to MEN1, with no crossovers in our set of families. The 13 marker systems can be used for an accurate and reliable premorbid test for MEN1. In most clinical situations it is possible to identify a haplotype of this part of chromosome 11 with the mutant MENi allele in the middle. The calculated predictive accuracy is > 99.5% if three such marker systems are informative. Therefore, genetic linkage testing can be used for informed genetic counseling in MENi families, and to avoid unnecessary biochemical screening programs. (J. Clin. Invest. 1992.
Introduction
Multiple endocrine neoplasia type 1 (MEN 1)1 is a genetic disorder characterized by neoplastic lesions in the parathyroid glands, the neuro endocrine pancreas, and the anterior lobe of the pituitary gland (1, 2) . We previously mapped the MEN1 locus to chromosomal region 1 lq l-q 1 3 by genetic linkage to restriction fragment length polymorphism (RFLP) markers in families segregating the disease (3) . By identifying meiotic crossovers in MEN 1 families, we were able to locate the disease gene close to the PYGM locus and flanked by the Dl 1S288 locus located 7 cM on the centromeric side, and by INT2 7 cM on the telomeric side ofthis marker (4) (Fig. 1) . Furthermore, comparisons of the genotypes in normal and tumor tissue from the same individual showed that the pathogenesis ofpancreatic, as well as parathyroid lesions, involve unmasking of a recessive mutation at the MEN1 locus (3, (5) (6) (7) (8) , in agreement with the two-mutational model originally postulated by Knudson (9) . Deletion mapping of two MEN1-associated lesions suggested that the MEN 1 locus is telomeric to PYGM, and within the 5 cM interval between PYGM and Dl 15146 (4, 7) .
Based on the autosomal dominant mode of inheritance, offspring ofMENl patients have a risk ofclose to 50% ofdeveloping the disease. Affected individuals may present with any of the MEN 1-associated lesions in early teenage, or escape clinical symptoms for several decades. Children of MEN 1 patients usually undergo repeated biochemical screenings in order to identify lesions as early as possible (10) . However DNA probes, genotyping, and linkage analysis. The probes used and the RFLP's detected with these markers are described in Table I (12) . Table I includes only those 17 probes which showed significant linkage to the MEN1 locus (see below). For 10 ofthe probes listed previously published RFLPs existed (12, 17, 18) . New allele systems were identified through locus expansion in cosmids for PGA (cCLPGA12), PYGM (cCL15), Dl IS146 (cCL59), and Dl1IS751 (cCL8), and the new cosmid Dl lS750/cCLGW4 was isolated from a library constructed from radiation-reduced somatic cell hybrids containing the 1 lq I I -q 13 region ( 14) .
The gene order given for the markers in Table I from the centromere (top) is according to the combined data for RFLP mapping using reference families (4, 1 1), physical mapping data from hybrid cell panels, and long-range restriction enzyme mapping with pulsed-field gel electrophoresis (13, 14) . Seven "anchor" markers indicated in bold are those probes mapped by linkage in reference families ( 11) (Fig. 1) . In the following, the same gene order is used in tables and figures.
Only marker systems that gave significant linkage to MEN1 are listed in Table I . As shown, three marker systems (Dl lS146, Dl 1S75 1, and INT2) with two separate 2-allele RFLP's were combined to 4-allele systems by haplotyping. For the markers Dl1 S288 and D 1 S 149 previous linkage data in reference families have shown a very close linkage with no meiotic crossover between these two loci (4, 1 1). Similarly, we have not detected any recombinations between these markers in our MEN1 families. Therefore, these two markers were also combined by haplotyping, in order to increase their relative information content. Haplotyping ofthe two markers for the PYGM locus and the combined Dl lS97 + Dl lS146 markers is also possible, although we have chosen to analyze them separately since the information content was high for each one of these markers.
Methods and conditions for DNA preparation, Southern blotting, hybridization to radioactively labeled DNA probes, and autoradiography were as described ( 14) . Several ofthe markers used contained repetitive DNA elements (marked with § in Table I ), and were therefore hybridized in the presence of denatured, sonicated human DNA.
Family and genotype data were typed into the linkage data managing computer database "LINKSYS." Two-point linkage between Results Linkage to MEN]. A number of DNA markers mapped within, or close to, chromosome bands 1 q 1 -q 13 were tested for linkage to the disease in six MEN1 families. 13 marker systems gave significant lod scores (Table II) . Three pedigrees from Sweden (LU, KA, and EZ) previously outlined in the original mapping of MEN1 (3) were reanalyzed, since some of the marker systems used may be more informative ifthe experimental conditions are adjusted. In addition, two new Swedish families (AX and RA) (Fig. 2) and part of one large MEN1 pedigree from Tasmania were studied (15 (3, 4) . Four newly isolated cosmid probes, cCLl5 for PYGM, Dl 1S427, Dl 1S449, and DlIS750, gave lod scores in the range of 3-5. The lower lodscores for these markers are in part due to the fact that they are less informative than the multiallele VNTR detected by the PYGM probe pMCMPl. DNA criteria. Hence, in these kindred the DNA-based testing uses the first affected child as reference case.
For each additional child, the carrier status for MEN 1 can now be inferred from its haplotype of these marker systems. This is illustrated in the RA kindred, where the first daughter who inherited MEN 1 from her mother also inherited the 2-allele for the PYGM marker cCL1 5, and the 3-allele for D 1I S427. In addition, the 1-allele for PGA and the 3-allele for Dl 1S97 were linked to the disease. The younger brother had inherited the same haplotype as his affected sister. The most likely interpretation of these data is that he has inherited a nonrecombinant stretch ofthis chromosome region, including all loci from PGA to Dl 1S97. Hence, this would also include the MEN1 mutation. The predicted MEN1 diagnosis is confirmed for this boy, who underwent surgery for primary hyperparathyroidism, and treated for prolactinoma. Since four markers were used, two very close to MEN 1 and two flanking the disease locus, this family illustrates not only the use of the very closely linked markers cCL1 5 and Dl 1S427 for genetic testing, but also that meiotic crossovers close to MEN1 could be excluded.
If a crossover had occurred in the second child, this would only escape detection if the first child also had inherited a recombinant chromosome with the crossover point between the same two markers. In this case then, an incorrect prediction of the disease predisposition in the second child could only occur ifboth children had inherited recombinant chromosomes. The probability for this is < 0.003, based on the linkage map shown in Fig. 1 . Furthermore, this would only result in incorrect prediction in the instance that the one of these crossover events had occurred between the disease locus and the two marker loci PYGM and D 1I S427, for which no recombinant has yet been found. In the RA family, the third and still unaffected 24-yr-old child (marked with ?) is predicted to carry the disease gene based on the genotype data (Fig. 2) .
In each ofthe following kindred outlined in Fig. 1 that the DNA testing for MENI is based on at least one marker which shows no crossover with the disease locus, and at least one marker flanking the disease on each side of the disease locus. Thus, we excluded crossovers close to MEN 1 in each of these kindreds. As illustrated in the KA-2 kindred, a meiotic crossover had occurred in the fifth daughter between DI S288 and PGA. Since the point of crossover could be located in this girl, we could then use six alternative markers beyond this point, PGA, PYGM, D1 1S427, D1IS750, D1IS97, and Dl1 S146, and found no evidence for crossing over for any of these markers. The set ofsix families outlined in Fig. 2 illustrate how DNA testing for MEN 1 would be possible to use for predictive testing. In 16 offsprings (all children except one in each family) we know the outcome of 13 based on clinical and biochemical data. In all these cases the DNA test was totally conclusive based on a set ofat least one closely linked probe, (0 = 0%) and two flanking probes in all instances (Fig. 2) . Hence, the set of markers described here (Table I (Table II) . The 17 probes studied in this report include 7 anchor markers which have been ordered by multipoint linkage analysis (11) . All probes used here have also been mapped physically within the 1 lq 12-q 13 region (12) (13) (14) . The gene orders, as determined by physical mapping (13, 14) and genetic linkage data (4, 1 1) are in full agreement with the data presented here.
As illustrated in Fig. 2 Hence, we are not only able to determine the linkage phase, using at least one very close marker system (with no crossover with MEN 1), but also to detect if a meiotic crossover event has occurred within the chromosomal region flanking the MEN1 locus. Until the disease gene has been cloned, predictive DNA testing for MEN1 should be supported by at least one closely linked marker and one flanking marker on each side of the disease locus, in order to avoid incorrect diagnosis due to meiotic crossing over. In this instance, the reliability ofthe prediction will exceed 99.5%, which is a common level for inaccuracies due to sample mixing or incorrect diagnosis of patients.
In conclusion, the marker systems in Table II that show recombination fractions of-oo are located outside the MEN 1 region based on meiotic crossovers. Therefore, we would like to stress that predictive testing for MEN 1 should not be based on linkage to these markers alone. Instead, these markers are to be used as indicators of crossing over close to MEN 1, in order to identify matings where predictive testing can not be considered reliable.
Finally, one should not exclude the possibility that meiotic crossing over may occur between MEN1 and any of the five markers closest to the disease locus. In a clinical test situation, this will not pass undetected if the setup illustrated in Fig. 2 is used. On the other hand, any such crossover will be a key finding for further locating the MEN1 gene within this region, and will facilitate the final cloning of the MENI gene.
